Expert regional community oncologist examines the grading and management of early adverse events such as CRS and ICANS, discussing the national guidelines that are utilized.
Videos
Expanding on the roles and responsibilities for executing a bispecifics administration program, highlighting a multidisciplinary collaboration to establish SOPs, training, and education.
BCG-unresponsive non-muscle invasive bladder cancer has multiple emerging treatment options in trials showing good response rates, though optimal sequencing remains to be determined.
Dr. Peters shares her experience in SOPs and program development for administration of bispecific T-cell engagers, noting program champions and key program components.
TAR-200 is being studied for carcinoma in situ with or without papillary disease since it addresses diffuse CIS that cannot be surgically removed, though future trials will expand to papillary disease as adjuvant therapy like BCG, with the goal of extending the disease-free period before potentially reintroducing therapy as needed.
Brooke Peters, PharmD, BCOP, provides a comprehensive overview of her institution’s bispecifics administration program, highlighting several agents and the hematologic/oncologic conditions they treat.
Justin LaPorte, PharmD, BCOP, offers closing remarks following discussion on the administration of bispecific antibodies.
A clinical pharmacist explains how their practice has evolved related to the administration of bispecific T-cell engagers.
Justin LaPorte, PharmD, BCOP, presents information on the grading and management of early and late adverse events.
Discussion of the roles and responsibilities of the health care provider (physician, APP), pharmacy staff, nursing staff, and financial counselors/clinic financial manager in bispecific engager administration.
Justin LaPorte, PharmD, BCOP, further explores his experience in developing and/or executing program development and SOPs for bispecific engagers.
A description and overview of the bispecific engager administration program at Northside Hospital.
Justin LaPorte, PharmD, BCOP, introduces the purpose and objectives for the program.
John M. Burke, MD, discusses the 2 phase 3 trials presented at the 2023 ASH Annual Meeting that have potential to be practice changing for patients with multiple myeloma and chronic lymphocytic leukemia.
Anne Chiang, MD, PhD, discusses the takeaways from her presentation given at the 18th Annual New York Lung Cancers Symposium.
Stephen Schuster, MD, discusses findings from follow-up of the phase 2 ELARA study presented at the 2023 ASH Annual Meeting.
David J. Andorsky, MD, discusses findings from a retrospective study of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma from ASH 2023.
Habte Yimer, MD, discusses findings from follow-up data of the phase 3 ALPINE study that were presented at the 2023 ASH Annual Meeting.
Gabriel Hortabagyi, MD, provides an update on data from the phase 3 NATALEE trial of ribociclib and endocrine therapy in patients with early breast cancer.
Amer Assal, MD, discusses recent advancements in the field of bone marrow and stem cell transplants at the American Society of Hematology 2023 Annual Meeting.
Sabarish Ram Ayyappan, MD, discusses findings from the final analysis of the phase 2 ELM-2 trial of odronextamab in a cohort of patients with relapsed/refractory diffuse large B-cell lymphoma.
Andrew Srisuwananukorn, MD, discusses the main findings from research of an artificial intelligence-powered machine learning algorithm which evaluated digital whole-slide images of diagnostic bone marrow biopsies and accurately differentiated prefibrotic primary myelofibrosis from essential thrombocythemia.
Evandro D. Bezerra, MD, provides real-world data from the CIBMTR Registry, examining the effectiveness of brexucabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Guenther Koehne, MD, PhD, discusses findings from a phase 1/2 trial that are being presented at the American Society of Hematology 2023 Annual Meeting.
A comprehensive overview of third-line relapsed/refractory DLBCL treatment options, including CAR T-cell therapy and bispecific antibodies.
Expert Matthew Lunning, DO, FACP, reviews the case of a 73-year-old woman with R/R DLBCL, considering current and emerging treatment strategies in this setting.
Anthony Hunter, MD, discusses JAK inhibitor resistance and optimal strategies for treatment of patients with myelofibrosis.
Dr. Paolo Tarantino offers expert guidance on optimizing outcomes for patients with ER+/HER2-low metastatic breast cancer.
A comprehensive review of the safety and efficacy from a HER2-low subgroup analysis in the EMERALD Trial presented at SABCS 2023 and clinical implications in practice.
Dr. Paolo Tarantino discusses the current treatment landscape of ER+/HER2- low metastatic breast cancer and unmet needs.